Press Releases

Nivalis Therapeutics to Present at Two Upcoming Investor Conferences

BOULDER, Colo., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS), a clinical stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today announced that Chief Executive Officer, Jon Congleton will present a corporate overview at the 25th Annual Credit Suisse Healthcare Conference and the Stifel 2016 Healthcare Conference.

Details of the two presentations are as follows:

25th Annual Credit Suisse Healthcare Conference
Date: Tuesday, November 8th
Location: The Phoenician, Arizona
Presentation Time: 4:00 PM MST

Stifel 2016 Healthcare Conference
Date: Tuesday, November 15th 
Location: The Lotte New York Palace Hotel, New York
Presentation Time: 10:15 AM EST

Individuals may access a live webcast of the conference presentations on the Nivalis website at www.nivalis.com under "IR Calendar" in the "News / Events" section.  A replay of the webcast will be available on this site for 90 days following the live event.

About Nivalis Therapeutics, Inc.

Nivalis Therapeutics, Inc. (http://www.nivalis.com) is a clinical stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

Contacts:

Investor Relations
John Graziano
1-646-378-2942
jgraziano@troutgroup.com

Media Relations
Lindsay Rocco
1-862-596-1304
lrocco@elixirhealthpr.com

Primary Logo

Source: Nivalis Therapeutics, Inc.

Leaving Nivalis.com

Nivalis Therapeutics is not responsible for the content on linked websites.

The document you requested is located on the Journal of Applied Physiology website. A subscription is required to view the document.